List of Excipients in Branded Drug CUVRIOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Orphalan SA	CUVRIOR	trientine tetrahydrochloride	81802-001	GLYCERYL DIBEHENATE	2029-04-28
Orphalan SA	CUVRIOR	trientine tetrahydrochloride	81802-001	MANNITOL	2029-04-28
Orphalan SA	CUVRIOR	trientine tetrahydrochloride	81802-001	SILICON DIOXIDE	2029-04-28

CUVRIOR Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

CUVRIOR is an oral trientine tetrahydrochloride tablet approved by the U.S. Food and Drug Administration for maintenance treatment of Wilson disease in adults and children at least 9 years old who are stable on chelation therapy and tolerant of treatment [1]. Its commercial position depends on lifelong use, strict separation from food and mineral supplements, pediatric dosing, and the practical advantages of a tablet over older trientine hydrochloride capsule products.

The strongest excipient opportunities are pediatric-friendly delivery systems, low-metal and low-reactivity manufacturing controls, adherence packaging, and formulations that reduce fasting-related administration problems. The principal commercial risk is generic or authorized-generic substitution after regulatory exclusivity and patent barriers weaken.

What is CUVRIOR and how is it used?

CUVRIOR contains trientine tetrahydrochloride, a copper-chelating agent. Trientine binds copper and promotes its urinary elimination. The product is used for maintenance therapy rather than initial treatment in patients who are clinically stable on chelation treatment [1].

Product attribute	CUVRIOR
Active ingredient	Trientine tetrahydrochloride
Dosage form	Oral tablet
Therapeutic area	Wilson disease
FDA approval	May 23, 2022
Marketing authorization holder	Orphalan
Pediatric use	Adults and children at least 9 years old
Administration	Divided daily doses on an empty stomach
Key interaction issue	Separation from food, iron, zinc, calcium and other mineral-containing products
Commercial category	Orphan, chronic-use specialty medicine

The label recommends administration at least one hour before meals or two hours after meals. CUVRIOR must be separated from iron supplements by at least two hours and from other mineral supplements by at least one hour [1].

These restrictions make formulation and packaging commercially relevant. The formulation must support chemical stability while the product presentation must help patients maintain a demanding dosing schedule.

What excipients are used in CUVRIOR tablets?

CUVRIOR uses conventional tablet excipients for compression, flow, lubrication, coating and physical stability. The FDA-approved labeling and product information identify inactive ingredients used in the tablet and film-coat system [1,2].

The excipient strategy can be assessed across five functions:

Excipient function	Commercial purpose
Dilution and compression	Produces a tablet with adequate mechanical strength and dose uniformity
Binder system	Supports granule or tablet integrity
Disintegration	Enables release of trientine after ingestion
Lubrication and flow	Supports high-throughput tablet manufacture
Film coating	Improves swallowability, appearance and handling

The central technical issue is not novelty of the individual excipients. It is compatibility with a highly water-soluble chelating compound, control of moisture exposure, and avoidance of trace-metal contamination during manufacturing.

Why low-metal excipient control matters

Trientine is intended to bind copper. Trace metals in excipients, processing equipment, water systems or packaging can affect assay results, impurity profiles and long-term stability. A robust CUVRIOR-like manufacturing platform should use:

• Qualified excipients with controlled elemental impurity profiles.
• Dedicated or validated equipment-cleaning procedures.
• Low-metal-contact process streams where practical.
• Tight controls for copper, iron, zinc, nickel and other elemental impurities.
• Packaging that limits moisture ingress.
• Stability studies linking excipient lots to assay and degradation behavior.

The issue is broader than compliance with ICH Q3D. Metal interaction can become a product-performance and batch-release risk for a chelator, particularly where the active ingredient is present at a comparatively high tablet load or where the product is manufactured in facilities handling mineral-containing materials [3].

What formulation patents may protect CUVRIOR?

CUVRIOR’s commercial protection may arise from several distinct layers:

1. Composition-of-matter protection for trientine tetrahydrochloride, where applicable.
2. Solid oral dosage-form claims.
3. Tablet composition and excipient-ratio claims.
4. Manufacturing-process claims.
5. Stability or impurity-control claims.
6. Method-of-use claims for maintenance treatment of Wilson disease.
7. Pediatric dosing or patient-selection claims.
8. Packaging and storage claims.

A formulation patent is more commercially meaningful when it claims a defined combination of trientine tetrahydrochloride, excipient classes, dissolution performance, impurity limits and stability outcomes. Broad claims covering routine pharmaceutical excipients are more vulnerable to invalidity or design-around arguments than claims tied to a demonstrated stability or bioavailability advantage.

Public patent analysis should distinguish between:

• Patents listed in the FDA Orange Book.
• Unlisted formulation or process patents.
• Pending applications.
• Continuations and divisionals.
• Orphan-drug exclusivity.
• Regulatory exclusivity that does not depend on patent validity.

An exact patent-expiration analysis requires current USPTO prosecution records, FDA Orange Book listings and terminal-disclaimer data. Patent expiry should not be inferred from the approval date alone.

When does CUVRIOR lose exclusivity?

CUVRIOR received FDA approval on May 23, 2022. Wilson disease products may qualify for orphan-drug exclusivity, which generally blocks FDA approval of the same drug for the same disease or condition for seven years from approval, subject to statutory exceptions [4].

If seven-year orphan exclusivity applies to the approved CUVRIOR indication, the nominal period would run to May 23, 2029. That date is separate from patent expiry and does not necessarily prevent all competing products. Orphan exclusivity can coexist with patent protection, pediatric exclusivity, new clinical investigation exclusivity and other FDA protections.

Protection type	Relevance to CUVRIOR
Orphan-drug exclusivity	Potentially important for Wilson disease approval protection
Patent protection	May cover formulation, use, process or dosage form
Pediatric exclusivity	Depends on FDA-granted pediatric studies and statutory requirements
New clinical investigation exclusivity	Depends on qualifying studies and regulatory status
Regulatory exclusivity	Must be checked in FDA records rather than inferred

What is the Orange Book status of CUVRIOR?

The Orange Book is the controlling FDA source for approved drug-product patent listings and therapeutic-equivalence information [5]. CUVRIOR’s competitive exposure should be assessed against the current listing for its NDA, including any listed patents, delisting events, expiry dates and certifications submitted by abbreviated new drug application applicants.

A Paragraph IV certification can trigger patent litigation if an ANDA applicant alleges that a listed patent is invalid, unenforceable or not infringed. The commercial effect depends on the timing of notice, litigation filing, a potential 30-month stay and the scope of the challenged claims under the Hatch-Waxman Act [6].

No commercial forecast should treat the seven-year orphan period as a complete substitute for Orange Book analysis. A generic applicant may challenge patents before orphan exclusivity ends, while a nonidentical product or alternative indication may present a different regulatory pathway.

Which companies compete with CUVRIOR?

CUVRIOR competes primarily with other trientine products and with penicillamine, not with biologics.

Product or category	Active ingredient	Dosage form	Competitive relevance
CUVRIOR	Trientine tetrahydrochloride	Tablet	Differentiated branded tablet
SYPRINE	Trientine hydrochloride	Capsule	Established trientine competitor
Generic trientine hydrochloride	Trientine hydrochloride	Capsule	Price and access pressure
Penicillamine products	Penicillamine	Tablet or capsule	Alternative chelation therapy
Zinc therapy	Zinc salts	Oral dosage forms	Maintenance option in selected patients

CUVRIOR’s tablet format may support easier handling than capsules, but its fasting requirements remain a major adherence constraint. Clinical substitution also depends on physician familiarity, insurance formularies, patient tolerability and dose conversion practices.

What excipient opportunities exist for CUVRIOR-like products?

Pediatric formulations

The largest formulation opportunity is a pediatric dosage form for children younger than 9 years old or for patients who cannot reliably swallow tablets. Potential platforms include:

• Oral granules.
• Sprinkle capsules.
• Mini-tablets.
• Powder sachets.
• Dispersible tablets.
• Compounded or pharmacy-prepared liquids.

Any liquid or dispersible system would require rigorous assessment of trientine compatibility, metal binding, pH effects, microbial stability, dosing uniformity and packaging interaction. A liquid formulation may improve administration but could create new stability and container-closure problems.

Mineral-compatible excipient systems

A differentiated excipient platform could reduce the risk of trace-metal interaction. Commercially useful controls may include:

• Low-elemental-impurity grades of common fillers.
• Chelator-compatible binders.
• Lubricants with controlled metal content.
• Low-moisture film-coating systems.
• Excipient supplier qualification based on copper and iron limits.

The value would be highest if the platform produces measurable improvements in shelf life, impurity control or manufacturing yield.

Adherence-oriented packaging

Packaging is a practical commercial opportunity because patients must separate CUVRIOR from meals and supplements. Useful designs include:

• Calendar blister packs.
• Morning and evening dose compartments.
• Explicit mineral-separation instructions.
• Travel packs with dosing reminders.
• Packaged instructions for fasting windows.
• Separate storage areas for mineral supplements.

Packaging claims may be difficult to protect broadly, but adherence packaging can support premium positioning and reduce medication errors.

Taste-masked and swallowability-enhanced products

Taste masking is relevant to pediatric and geriatric populations. However, conventional sweeteners, flavors and coating agents must be evaluated for chemical compatibility and for potential interactions with the active ingredient. A taste-masked liquid or multiparticulate product would need to preserve dose accuracy and avoid encouraging administration with food if fasting is required.

How strong is the CUVRIOR patent estate?

The commercial strength of CUVRIOR’s estate depends on claim breadth, remaining patent term, Orange Book listing status, prosecution history and the ability to design around the tablet composition.

A strong estate would typically include:

• Claims directed to the specific trientine salt.
• Claims covering a defined tablet composition.
• Stability claims tied to measurable degradation limits.
• Manufacturing claims that competitors cannot easily avoid.
• Method-of-use claims covering commercially important patient populations.
• Multiple patent families with staggered expiry dates.

An estate based mainly on routine tablet excipients may provide narrower protection. Generic applicants can often substitute equivalent fillers, binders or disintegrants unless the patent claims a critical composition range or a demonstrated performance parameter.

The most defensible formulation claims would likely be those connected to a technical problem: active degradation, hygroscopicity, dissolution control, impurity suppression, tablet hardness, or dose uniformity.

What generic launch risks exist?

Generic entry could occur through several routes:

1. An ANDA for a trientine tablet that meets the reference-product requirements.
2. A capsule product that competes therapeutically but is not pharmaceutically identical.
3. A Paragraph IV challenge to listed patents.
4. A product launched after patent expiry but before all commercial protections are exhausted.
5. A compounded or alternative dosage form targeting pediatric or swallowing-limited patients.
6. A product approved for a related but distinct indication.

The largest price risk is likely to emerge from capsule competition and authorized-generic strategies. The largest differentiation opportunity is likely to come from pediatric administration, packaging and improved adherence rather than from a simple substitution of standard tablet excipients.

What licensing and manufacturing opportunities exist?

Potential licensing targets include:

• Low-metal excipient technologies.
• Pediatric multiparticulate delivery systems.
• Specialized blister and adherence packaging.
• Stability-indicating analytical methods.
• CDMO capacity for high-containment or low-metal pharmaceutical manufacturing.
• Regional commercialization rights for Wilson disease products.
• Diagnostic and treatment-monitoring partnerships.

A licensee would likely value a platform that reduces development time and supports a second product generation. A basic excipient substitution is less attractive unless it improves cost, supply continuity or stability.

Manufacturing barriers are moderate rather than absolute. Standard oral-solid-dose manufacturers can produce a trientine tablet, but quality systems must address elemental impurities, active-excipient compatibility, cleaning validation and consistent control of moisture.

How does CUVRIOR compare with SYPRINE?

Factor	CUVRIOR	SYPRINE
Trientine form	Tetrahydrochloride	Hydrochloride
Dosage form	Tablet	Capsule
FDA market position	Newer branded product	Older established product
Administration burden	Fasting and mineral separation	Similar chelation-related restrictions may apply
Formulation opportunity	Pediatric tablet, granules, packaging	Capsule reformulation and supply optimization
Generic exposure	Depends on patents and exclusivity	More mature generic and supply competition
Commercial differentiation	Tablet format and branded support	Established prescribing base

CUVRIOR’s advantage is product modernization. Its limitation is that the core treatment burden, especially fasting administration and mineral separation, remains.

Key Takeaways

• CUVRIOR is a trientine tetrahydrochloride tablet for maintenance treatment of Wilson disease.
• Its formulation value lies in stability, tablet performance and control of trace-metal contamination.
• Pediatric granules, mini-tablets, dispersible forms and oral liquids are the clearest product-development opportunities.
• Calendar packaging and dose-separation tools can address the product’s fasting and mineral-interaction requirements.
• FDA approval occurred on May 23, 2022. If orphan exclusivity applies, the nominal seven-year period would extend to May 23, 2029.
• Patent expiry cannot be determined from approval timing and must be separated from FDA exclusivity.
• Generic risk depends on Orange Book listings, Paragraph IV activity, formulation claim strength and the potential for capsule or alternative-dosage-form competition.
• The strongest formulation patents would tie excipient selection to measurable stability, impurity, dissolution or manufacturing advantages.

FAQs

Can CUVRIOR be reformulated as an oral liquid?

Yes, but an oral liquid would require development work on chemical stability, elemental impurities, microbial control, dosing accuracy, packaging and compatibility with the required fasting administration.

Are excipients likely to drive a generic CUVRIOR product’s competitive advantage?

Yes. A generic company may gain an advantage through lower-cost excipients, higher-yield processing, improved tablet robustness or a differentiated pediatric presentation, provided the product meets FDA equivalence requirements.

Could a low-metal excipient platform support a new CUVRIOR patent?

Potentially. Patent value would depend on whether the platform produces a non-obvious and measurable improvement in stability, impurity control, dissolution, bioavailability or manufacturing performance.

Is CUVRIOR suitable for a biosimilar strategy?

No. CUVRIOR is a small-molecule oral drug, not a biologic. Competition would generally involve generic, hybrid, 505(b)(2), reformulated or otherwise abbreviated drug-development pathways rather than biosimilar approval.

What is the most attractive commercial opportunity around CUVRIOR?

A pediatric and adherence-focused product platform is the most attractive opportunity. It could combine a child-appropriate dosage form, low-metal excipient controls and packaging that manages fasting and mineral-separation requirements.

References

1. U.S. Food and Drug Administration. (2022). CUVRIOR (trientine tetrahydrochloride) tablets: Prescribing information.
2. DailyMed. (2022). CUVRIOR- trientine tetrahydrochloride tablet, film coated. U.S. National Library of Medicine.
3. International Council for Harmonisation. (2014). ICH Q3D(R2): Guideline for elemental impurities.
4. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Code, 21 U.S.C. § 355(j). Abbreviated applications for new drugs.